Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3897125 | 0.83 | CLK1 (0.32) | — | |
| SCHEMBL2957 | 0.73 | CYP2A6 (0.32) | LMNACYP1A2CYP3A4CYP2D6KDM4E | |
| SCHEMBL28068731 | 0.71 | KDM4E (0.31) | LMNACYP1A2CYP3A4CYP2D6KDM4E | |
| Hydrochloric Acid SCHEMBL28618702 | 0.71 | KDM4E (0.33) | LMNACYP1A2CYP3A4CYP2D6KDM4E | |
| SCHEMBL159538 | 0.71 | PRKCZ (0.33) | LMNACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL27674458 | 0.70 | PRKCZ (0.32) | LMNACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL275946 | 0.68 | LMNA (0.33) | LMNACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL89121 | 0.66 | CYP19A1 (0.39) | LMNACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL30571321 | 0.66 | CYP19A1 (0.39) | LMNACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL29559681 | 0.66 | CYP19A1 (0.39) | LMNACYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230102554-A1 | HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF | GB002, INC. | 2023-03-30 | — | — | US | claimed |
| EP-3990443-A1 | HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF | GB002, Inc. (US) | 2022-05-04 | — | — | EP | claimed |
| US-20210196717-A1 | TOLL-LIKE RECEPTOR 4 (TLR4) INHIBITORS AND USE THEREOF | BAR-ILAN UNIVERSITY (IL) | 2021-07-01 | — | — | US | claimed |
| EP-3797100-A1 | TOLL-LIKE RECEPTOR 4 (TLR4) INHIBITORS AND USE THEREOF | Mor Research Applications Ltd. (IL) | 2021-03-31 | — | — | EP | claimed |
| WO-2020264420-A1 | HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF | GB002, INC. (US) | 2020-12-30 | — | — | WO | claimed |
| US-11925643-B2 | Toll-like receptor 4 (TLR4) inhibitors and use thereof | MOR RESEARCH APPLICATIONS LTD. (IL) | 2024-03-12 | — | — | US | disclosed |
| US-20230102554-A1 | HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF | GB002, INC. | 2023-03-30 | — | — | US | disclosed |
| WO-2022128850-A1 | NOVEL ISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2022-06-23 | — | — | WO | disclosed |
| EP-3990443-A1 | HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF | GB002, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| US-20210196717-A1 | TOLL-LIKE RECEPTOR 4 (TLR4) INHIBITORS AND USE THEREOF | BAR-ILAN UNIVERSITY (IL) | 2021-07-01 | — | — | US | disclosed |
| EP-3797100-A1 | TOLL-LIKE RECEPTOR 4 (TLR4) INHIBITORS AND USE THEREOF | Mor Research Applications Ltd. (IL) | 2021-03-31 | — | — | EP | disclosed |
| WO-2020264420-A1 | HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF | GB002, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| US-6992069-B2 | Tricyclic macrolide antibacterial compounds | ABBVIE INC. | 2006-01-31 | — | — | US | disclosed |
| US-6933283-B2 | 11-deoxy azalide antibacterials | ABBOTT LABORATORIES (US) | 2005-08-23 | — | — | US | disclosed |
| US-20040029818-A1 | Tricyclic macrolide antibacterial compounds | ABBVIE INC. | 2004-02-12 | — | — | US | disclosed |
| US-20040014687-A1 | Macrolide antibacterial compounds | ABBOTT LABORATORIES | 2004-01-22 | — | — | US | disclosed |
| US-20040014688-A1 | Oxolide antibacterials | ABBVIE INC. | 2004-01-22 | — | — | US | disclosed |
| US-20040014691-A1 | 9-Oxime macrolide antibacterials | ABBOTT LABORATORIES | 2004-01-22 | — | — | US | disclosed |
| US-20040014953-A1 | 11-Deoxy azalide antibacterials | ABBVIE INC. | 2004-01-22 | — | — | US | disclosed |
| US-20040009932-A1 | Antibacterial compounds with activity against penicillin-resistant streptococcus pneumoniae | ABBOTT LABORATORIES | 2004-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014691-A1 | 9-Oxime macrolide antibacterials | CYP2C9, CYP1B1, SULT1E1 | LMNA 2161/4885CYP1A2 65/4885CYP3A4 71/4885 |
| US-11925643-B2 | Toll-like receptor 4 (TLR4) inhibitors and use thereof | TLR4, TLR1, TLR3 | LMNA 3069/4885CYP1A2 4840/4885CYP3A4 3759/4885 |
| US-20040014687-A1 | Macrolide antibacterial compounds | MRPL21, NOP2, PIGS | LMNA 1003/4885CYP1A2 127/4885CYP3A4 246/4885 |
| US-20040029818-A1 | Tricyclic macrolide antibacterial compounds | RPN1, CASP1, MRPL21 | LMNA 1662/4885CYP1A2 179/4885CYP3A4 90/4885 |
| US-20040009932-A1 | Antibacterial compounds with activity against penicillin-resistant streptococcus pneumoniae | PGLS, GGPS1, CASP1 | LMNA 1573/4885CYP1A2 262/4885CYP3A4 399/4885 |
| US-20040014953-A1 | 11-Deoxy azalide antibacterials | TOP1, TOP2B, TOP2A | LMNA 2681/4885CYP1A2 166/4885CYP3A4 264/4885 |
| US-20210196717-A1 | TOLL-LIKE RECEPTOR 4 (TLR4) INHIBITORS AND USE THEREOF | TLR4, TLR1, TLR3 | LMNA 3069/4885CYP1A2 4840/4885CYP3A4 3759/4885 |
| US-20230102554-A1 | HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF | PDGFRB, PDGFRA, FGFR1 | LMNA 2517/4885CYP1A2 3184/4885CYP3A4 2040/4885 |
| US-20040014688-A1 | Oxolide antibacterials | OGFOD1, PGLS, OXER1 | LMNA 2757/4885CYP1A2 236/4885CYP3A4 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.